350 руб
Журнал «Вопросы биологической, медицинской и фармацевтической химии» №10 за 2011 г.
Статья в номере:
Система инсулиноподобных факторов роста и рак молочной железы
Ключевые слова: ИФР рецепторы ИФР ИФР-связывающие белки рак молочной железы таргетная противоопухолевая терапия
Авторы:
О.И. Костылева - к.м.н., ст.науч.сотрудник, лаборатория клинической биохимии, РОНЦ им. Н.Н.Блохина РАМН (Москва). E-mail: biochimia@mtu-net.ru А.В. Масляев - врач-ординатор хирургического отделения опухолей женской репродуктивной сферы, РОНЦ им. Н.Н.Блохина РАМН. E-mail: a-maslyaev@yandex.ru О.М. Кузнецова - к.б.н., доцент, кафедра биохимии, медицинский факультет, ГОУ ВПО РУДН (Москва). E-mail: biochimia@mtu-net.ru А.А. Тулеуова - к.м.н., соискатель, кафедра клинической биохимии и лабораторной диагностики, факультет последипломного образования (ФПДО), ГБОУ ВПО «Московский государственный медико-стоматологический университет» (МГМСУ) Минздравсоцразвития РФ. E-mail: biochimia@mtu-net.ru У.Р. Мамедов - к.м.н., врач-ординатор хирургического отделения опухолей молочных желез, РОНЦ им. Н.Н.Блохина РАМН. E-mail: biochimia@mtu-net.ru И.В. Терешкина - к.м.н., соискатель, кафедра клинической биохимии и лабораторной диагностики, ФПДО МГМСУ Минздравсоцразвития РФ. E-mail: biochimia@mtu-net.ru Т.Т. Березов - академик РАМН, д.м.н., профессор, кафедра биохимии, лечебный факультет, ГОУ ВПО РУДН. E-mail: biochimia@mtu-net.ru
Аннотация:
Рассмотрены множественное воздействие на ИФР-сигнальный путь, в частности, редукцию и нейтрализацию ИФР-лиганда, подавляющую регуляцию и конкурентное связывание с ИФР-рецептором, а также развитие ИФР-независимых антагонистических стратегий.
Страницы: 13-20
Список источников
  1. Alberobello A.T., D'Esposito V., Marasco D. et al. Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death // J. Biol. Chem. 2010. V. 285. № 9. P. 6563-6572.
  2. Arnold J.T., Le H., McFann K.K., Blackman M.R. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells // Am. J. Physiol. Endocrinol. Metab. 2005. V. 288. № 3. P. 573-584.
  3. Baglietto L., English D.R., Hopper J.L. et al. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer // Cancer Epidemiol. Biomarkers Prev. 2007. V. 16. № 4. p. 763-768.
  4. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer // Curr. Pharm. Des. 2007. V. 13. № 7. P. 671-686.
  5. Bonanni B., Johansson H., Gandini S. et al. Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women // Breast Cancer Res. Treat. 2001. V. 69. № 1. P. 21-27.
  6. Camirand A., Zakikhani M., Young F. et al. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells // Breast Cancer Res. 2005. V. 7. № 4. P. 570-579.
  7. Campbell C.I., Petrik J.J., Moorehead R.A. ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis // Molecular Cancer. 2010. V. 9. № 1 P. 235-251.
  8. Campbell M.J., Woodside J.V., Secker-Walker J. et al. IGF status is altered by tamoxifen in patients with breast cancer // Mol. Pathol. 2001. V. 54. № 5. P. 307-310.
  9. Chen C., Freeman R., Voigt L.F. et al. Prostate Cancer Risk in Relation to Selected Genetic Polymorphisms in Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-3, and Insulin-like Growth Factor Receptor // Cancer Epidemiol. Biomarkers Prev. 2006. V. 15. P. 2461-2466.
  10. Chen C., Lewis S.K., Voigt L.F. et al. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein-3, and insulin // Cancer. 2004. V. 103. № 1. p. 76-84.
  11. Ciftci K., Su J., Trovitch P.B. Growth factors and chemotherapeutic modulation of breast cancer cells // J. Pharm. Pharmacol. 2003. V. 55. № 8. P. 1135-1141.
  12. da Silva B.B., Moita D.S., Pires C.G. et al. Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene // Int. Semin. Surg. Oncol. 2007. V. 4. p. 18.
  13. Key T.J., Appleby P.N., Reeves G.K., Roddam A.W. et al. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies // Lancet Oncol. 2010. V. 11. № 6. P. 530-42.
  14. Eng-Wong J., Hursting S.D., Venzon D. et al. Effect of Raloxifene on Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Leptin in Premenopausal Women at High Risk for Developing Breast Cancer // Cancer Epidemiol. Biomarkers Prev. 2003. V. 12. p. 1468-1473.
  15. Frasca F., Pandini G., Sciacca L. et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases // Arch. Physiol. Biochem. 2008. V. 114. № 1. P. 23-37.
  16. Freedland S.J., Aronson W.J. Examining the Relationship Between Obesity and Prostate Cancer // Rev. Urol. 2004. V. 6. № 2. p. 73-81.
  17. Fürstenberger G., Senn E., Morant R. et al. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer // Breast. 2006. V. 15. № 1. p. 64-68.
  18. Grimberg A. Mechanisms by which IGF-I may promote cancer // Cancer Biol. Ther. 2003. V. 2. № 6. p. 630-635.
  19. Gu F., Schumacher F.R., Canzian F. et al. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer // Cancer Epidemiol Biomarkers Prev. 2010. V. 19. № 11. P. 2877-2887.
  20. Guerreiro A.S., Boller D., Doepfner K.T., Arcaro A. IGF-IR: potential role in antitumor agents // Drug News Perspect. 2006. V. 19. № 5. P. 261-272.
  21. Haffner M.C., Petridou B., Peyrat J.Ph. et al. Favorable prognostic value of SOCS2 and IGF-I in breast cancer // BMC Cancer. 2007. V. 7. Р. 136.
  22. Hartog H., Wesseling J., Boezen H.M. et al. The insulin-like growth factor 1 receptor in cancer: old focus, new future // Eur. J. Cancer. 2007. V. 43. № 13. p. 1895-1904.
  23. Holly J., Perks C. The role of insulin-like growth factor binding proteins // Neuroendocrinology. 2006. V. 83. № 3-4. P. 154-160.
  24. Ibrahim Y.H., Yee D. Insulin-like growth factor-I and breast cancer therapy // Clin. Cancer Res. 2005. V. 11. № 2(Pt 2). p. 944-950.
  25. Jameel J.K., Rao V.S., Cawkwell L., Drew P.J. Radioresistance in carcinoma of the breast // Breast. 2004. V. 13(6). P. 452-460.
  26. Johansson H., Baglietto L., Guerrierri-Gonzaga A. et al. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer // Breast Cancer Res. Treat. 2004. V. 88. № 1. p.63-73.
  27. Kahán Z., Gardi J., Nvári T. et al. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study // Int. J. Oncol. 2006. V. 29. № 1. p. 193-200.
  28. Larsson O., Girnita A., Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer // Br. J. Cancer. 2007. V. 96 (Suppl.). P. 2-6.
  29. Laviola L., Natalicchio A., Giorgino F. The IGF-I signaling pathway // Curr. Pharm. Des. 2007. V. 13. № 7. P. 663-669.
  30. Levitt R.J., Buckley J., Blouin M.J. et al. Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression // Biochem. Biophys. Res. Commun. 2004. V. 316. № 2. P. 421-428.
  31. Ling Y., Maile L.A., Clemmons D.R. Tyrosine phosphorylation of the ß3-subunit of the αVß3 integrin is required for membrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor I receptor // Mol. Endocrinol. 2003. V. 17. P. 1824-1833.
  32. Moschos S.J., Mantzoros C.S. The role of the IGF system in cancer: from basic to clinical studies and clinical applications // Oncology. 2002. V. 64. P. 317-332.
  33. Pavelić J., Matijević T., Knezević J. Biological & physiological aspects of action of insulin-like growth factor peptide family // Indian J. Med. Res. 2007. V. 125. № 4. p. 511-522.
  34. Paz K., Hadari Y.R. Targeted therapy of the insulin-like growth factor-1 receptor in cancer // Comb. Chem. High Throughput Screen. 2008. V. 11. № 1. p. 62-69.
  35. Pazaitou-Panayiotou K., Kelesidis T., Kelesidis I. et al. Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer // Eur. J. Endocrinol. 2007. V. 156. № 2. p. 187-94.
  36. Platz E.A., Pollak M.N., Leitzmann M.F. et al. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era // Cancer Causes Control. 2005. V. 16. № 3. p. 255-262.
  37. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia // Nat. Rev. Cancer. 2004. V. 4. P. 505-518.
  38. Probst-Hensch N.M., Steiner J.H., Schraml P. et al. IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity // Clin Cancer Res. 2010. V.16. № 3. P. 1025-1032.
  39. Prueitt R.L., Boersma B.J., Howe T.M. et al. Inflammation and IGF-I activate the Akt pathway in breast cancer // Int. J. Cancer. 2007. V. 120. № 4. p. 796-805.
  40. Rajski M., Zanetti-Dällenbach R., Vogel B. et al. IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients // BMC Med. 2010. V. 5. № 8. № 1. P. 18-36.
  41. Ren Z., Shin A., Cai Q. et al. IGFBP3 mRNA expression in benign and malignant breast tumors // Breast Cancer Res. 2007. V. 9. № 1. p. 2-11.
  42. Renehan A.G., Zwahlen M., Minder C. et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis // Lancet. 2004. V. 363. № 9418. p. 1346-1353.
  43. Rollison D.E., Newshaffer C.J., Tao Y. et al. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer // Int. J. Cancer. 2006. V. 118. № 5. p. 1279-1284.
  44. Samani A.A., Yakar S., LeRoith D. et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights // Endocr. Rev. 2007. V. 28. № 1. P. 20-47.
  45. Schernhammer E.S., Holly J.M, Hunter D.J. et al. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II // Endocr. Relat. Cancer. 2006. V. 13. № 2. p. 583-592.
  46. Singer C.F., Mogg M., Koestler W. et al. Insulin-Like Growth Factor (IGF)-I and IGF-II Serum Concentrations in Patients with Benign and Malignant Breast Lesions // Clin. Cancer Res. 2004. V. 10. p. 4003-4009.
  47. Sisci D., Surmacz E. Crosstalk between IGF signaling and steroid hormone receptors in breast cancer // Curr. Pharm. Des. 2007. V. 13. № 7. P. 705-717.
  48. Smith J., Axelrod D., Singh B., Kleinberg D. Prevention of breast cancer: the case for studying inhibition of IGF-1 actions // Ann. Oncol. 2011. Suppl. 1. P. 50-52.
  49. Ulanet D.B., Ludwig D.L., Kahn C.R., Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy // Proc. Natl. Acad. Sci. USA. 2010. V. 107. № 24. P. 10791-10798.
  50. Varela-Nieto I., Hartl M., Gorospe I., Leon Y. Anti-apoptotic actions of insulin-like growth factors: lessons from development and implications in neoplastic cell transformation // Curr. Pharm. Des. 2007. V. 13. № 7. P. 687-703.
  51. Vestey S.B., Perks C.M., Sen Ch. et al. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome // Breast Cancer Res. 2005. V. 7. № 1. p. 119-129.
  52. Weiss J.M., Huang W.Y., Rinaldi S. et al. IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial // Int. J. Cancer. 2007. V. 121. № 10. P. 2267-2273.
  53. Werner H. and Bruchim I. Basic and clinical significance of IGF-I-induced signatures in cancer // BMC Med. 2010. V. 8. № 1. P. 2-18.
  54. Werner H., Maor S. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action // Trends Endocrinol. Metab. 2006. V. 17. № 6. p. 236-242.
  55. Yakar S., Leroith D., Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models// Cytokine Growth Factor Rev. 2005. V. 16. P. 407-420.
  56. Zhang S., Li X., Burghardt R. et al. Role of estrogen receptor (ER) alpha in insulin-like growth factor (IGF)-I-induced responses in MCF-7 breast cancer cells // J. Mol. Endocrinol. 2005. V. 35. № 3. P. 433-447.
  57. Zhang X., Yee D. Tyrosine kinase signalling in breast cancer: Insulin-like growth factors and their receptors in breast cancer // Breast Cancer Res. 2000. V. 2. № 3. p. 170-175.